.Attributes Medicine, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Standpoint asks for inclusion of clients with MASLD and measurement of liver end results in cardio-- renal-- metabolic trials, when information propose mechanistically possible advantages and professional safety-- as well as lays out factors for trial design and also regulative approval.